For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Other Questions

Back to Help Center

Are patients on drug treatments when we look at the progression-free survival graph?

Yes, probably the patient would be taking some form of drug treatment when we look at the progression-free survival graph. Basically, the patients were not treatment free at the time.

How do we ship?

Please follow these steps to prepare the box and ship the sample to our lab. (Click to read more)

Would we need to set up a Vet Portal for each doctor or just our hospital?

If you would like to set up accounts for the hospital, please send us a list of doctors' names and email addresses as well as any support staff who would need access to the Vet Portal. Each doctor can also register independently on the Vet Portal. Please note the report will be sent to the ordering veterinarian's email, not to all hospital accounts.

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.